Efficacy and Safety of TF002 in Cutaneous Mastocytosis

Summary

The current study will investigate the effects of TF002 on cutaneous mastocytosis or cutaneous involvement of systemic mastocytosis as compared to clobetasol proprionate (positive control) and a general skin care product without active ingredient targeting mastocytosis (negative control) based on clinical effects on Darier´s signs and the histological evaluation of mast cell numbers in skin bioptic material.

Timeline

Start

2007-04

Primary completion

—

Completion

2007-09

Drugs

Indications